Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Assets (2016 - 2025)

Historic Assets for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $4.6 billion.

  • Neurocrine Biosciences' Assets rose 2454.62% to $4.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.6 billion, marking a year-over-year increase of 2454.62%. This contributed to the annual value of $4.6 billion for FY2025, which is 2454.62% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Assets stood at $4.6 billion, which was up 2454.62% from $4.3 billion recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Assets ranged from a high of $4.6 billion in Q4 2025 and a low of $1.8 billion during Q1 2021
  • Moreover, its 4-year median value for Assets was $3.3 billion (2024), whereas its average is $3.2 billion.
  • Per our database at Business Quant, Neurocrine Biosciences' Assets skyrocketed by 4714.81% in 2024 and then soared by 620.03% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Assets stood at $2.0 billion in 2021, then surged by 61.18% to $3.3 billion in 2023, then grew by 14.37% to $3.7 billion in 2024, then grew by 24.55% to $4.6 billion in 2025.
  • Its Assets stands at $4.6 billion for Q4 2025, versus $4.3 billion for Q3 2025 and $3.9 billion for Q2 2025.